Krystal Biotech Stock Piotroski F Score

KRYS Stock  USD 182.29  4.19  2.35%   
This module uses fundamental data of Krystal Biotech to approximate its Piotroski F score. Krystal Biotech F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Krystal Biotech. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Krystal Biotech financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Krystal Biotech Altman Z Score, Krystal Biotech Correlation, Krystal Biotech Valuation, as well as analyze Krystal Biotech Alpha and Beta and Krystal Biotech Hype Analysis.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.
  
Short Term Debt is likely to gain to about 4.4 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 7.6 M in 2024. At this time, Krystal Biotech's Graham Number is comparatively stable compared to the past year. Shareholders Equity Per Share is likely to gain to 30.11 in 2024, whereas Free Cash Flow Yield is likely to drop (0.03) in 2024.
At this time, it appears that Krystal Biotech's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
Current Return On Assets

Positive

Focus
Change in Return on Assets

Increased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Decreasing

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Krystal Biotech Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Krystal Biotech is to make sure Krystal is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Krystal Biotech's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Krystal Biotech's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.02830.0558
Way Down
Slightly volatile
Gross Profit Margin0.720.85
Fairly Down
Very volatile
Total Current Liabilities34.7 M33.1 M
Sufficiently Up
Slightly volatile
Total Assets859.3 M818.4 M
Sufficiently Up
Slightly volatile
Total Current Assets617.3 M587.9 M
Sufficiently Up
Slightly volatile

Krystal Biotech F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Krystal Biotech's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Krystal Biotech in a much-optimized way.

About Krystal Biotech Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

30.11

At this time, Krystal Biotech's Book Value Per Share is comparatively stable compared to the past year.

Krystal Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Krystal Biotech from analyzing Krystal Biotech's financial statements. These drivers represent accounts that assess Krystal Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Krystal Biotech's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap232.8M880.6M1.6B2.0B3.4B3.5B
Enterprise Value129.1M696.3M1.2B1.9B3.0B3.2B

Krystal Biotech ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Krystal Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Krystal Biotech's managers, analysts, and investors.
Environmental
Governance
Social

About Krystal Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.